AlphAIalphai — Financial news for AI agents
Stock TitanMAY 81 min read$GRDN

Guardian Pharmacy (GRDN) awards 4,028 restricted stock units to director

Guardian Pharmacy Services, Inc. (GRDN) director Steven D. Cosler was granted 4,028 restricted stock units (RSUs) as part of a compensation package. This award, valued at $0.00 per share, increases his direct holdings to 29,012 Class A common shares. The transaction was reported in a Form 4 filing, indicating a routine equity grant rather than a market purchase or sale.

Original reporting
Stock Titan
Published May 8, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 8, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$GRDN
Neutral
medium confidence
Mentioned
$GRDN
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$GRDNNeutralLow
01

Why it matters

This is a routine event with limited market impact, primarily reflecting internal compensation practices.

02

Market read

The event has minimal relevance to the broader market or sector, primarily of interest to company insiders and shareholders.

03

What to watch

Lack of information on current stock price and broader company performance limits the impact assessment.

Timing: low

Background

Guardian Pharmacy (GRDN) issued a Form 4 filing reporting an insider stock grant to its director.

Company-level read

Ticker impact

$GRDNNeutralMedium confidence
Context

The news pertains directly to Guardian Pharmacy (GRDN), indicating a routine insider stock grant.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

Insider stock grants are common and typically do not influence market prices unless accompanied by unusual trading activity or additional corporate news.

Market effects

Sector

Limited sector impact; routine insider transactions generally do not affect sector sentiment.

Regional

Minimal regional influence; specific to company insiders.

Global

Negligible; company-specific event with no broader market implications.

Counterpoint

What could challenge this read

Some investors might interpret insider stock grants as a sign of management confidence, potentially supporting the stock.

Key entities

  • Company
    Guardian Pharmacy Services, Inc.

    A pharmacy services provider.

  • Individual
    Steven D. Cosler

    Director of Guardian Pharmacy who received the stock units.

Read at source← All news

Related articles

AUG 8
$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

yahoo.com5 min
AUG 7
$GRDNMedAI 8/10

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

local3news.com2 min
AUG 6
$GRDNHigh

Guardian Pharmacy Services, Inc. (GRDN): Results of Operations and Financial Condition

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d160709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”)

SEC EDGAR 8-K4 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min